AstraZeneca to invest $2.5 billion in Beijing hub as it looks beyond Chinese tax probe

CNBC March 21, 2025
Chloe Taylor

Key Points

– British pharmaceutical giant AstraZeneca announced on Friday that it will invest $2.5 billion in a research and development center in Beijing, China.

– Under the deal, AstraZeneca will enter research and development collaborations with biotech firms Harbour BioMed and Syneron Bio and will launch a joint venture with BioKangtai to develop, produce, and market vaccines for respiratory and other infectious diseases.

AstraZeneca on Friday said that it will invest $2.5 billion in a research and development center in Chinese capital Beijing, months after the British pharmaceutical giant faced local regulators’ scrutiny over its import duties.

The new hub is expected to take AstraZeneca’s Beijing workforce to around 1,700 employees.

The investment in Beijing comes as part of...

Today's Sponsors

Today's Sponsor